EASTERN COOPERATIVE ONCOLOGY GROUP

东方肿瘤合作组

• 批准号: 7426310
• 负责人: Daniel George Haller
• 金额: $ 40.95万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1978
• 资助国家: 美国
• 起止时间: 1978-06-01 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7426310
• 关键词: Abdomen; Abramson Cancer Center at the University of Pennsylvania; Address; Adjuvant; Adjuvant Study; Administrator; Adopted; Adverse Drug Experience Report; Adverse event; African American; Alaska Native; Allogenic; American; American Indian and Alaska Native; American Indians; American Society of Clinical Oncology; Andro-Diane; Applications Grants; Area; Arts; Asians; Autologous Bone Marrow Transplantation; Award; Basic Science; Beds; Bibliography; Biology; Bone Marrow Transplantation; Breast; Budgets; Cancer Center; Cancer Control; Cancer Patient; Carboplatin/Paclitaxel; Cardiac; Categories; Cetuximab; Chest; Cisplatin/Paclitaxel; Clinic; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Clinical Trials Cooperative Group; Colon; Colon Carcinoma; Colon, Rectum; Colorectal; Colorectal Cancer; Commit; Communication; Community Outreach; Comprehensive Cancer Center; Core Facility; Daily; Data; Data Collection; Data Quality; Databases; Development; Diagnostic; Discipline of Nursing; Disease; Disorder by Site; Dose; Dysmyelopoietic Syndromes; Eastern Cooperative Oncology Group; Economics; Elderly; Eligibility Determination; Enrollment; Ensure; Environment; Equipment; Ethnic Origin; Ethnicity not Reported; Faculty; Family; Farnesyl Transferase Inhibitor; Female; Floor; Fluorouracil; Functional disorder; Funding; Future; Gastroenterology; Gender; Generations; Genitourinary system; Genus Cola; Geographic Locations; Gifts; Goals; Grant; Hawaiian population; Head and Neck Cancer; Hematologic Neoplasms; Hematology; Hematology, Other; Hispanics; Hospitals; Housing; Human Resources; Individual; Industry; Inpatients; Institutes; Institution; Intensive Care Units; Joints; Kidney; Laboratories; Latino; Lead; Leadership; Length; Location; Lung; Lymphocyte; Lymphoma; Malignant Neoplasms; Malignant neoplasm of esophagus; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of lung; Malignant neoplasm of pancreas; Malignant neoplasm of urinary bladder; Mastectomy; Master' s Degree; Medical; Medical Oncology; Mind; Minority; Modality; Modeling; Monitor; Multimodal Imaging; Names; National Cancer Institute; Native Hawaiian or Other Pacific Islander; Neoadjuvant Therapy; Not Hispanic or Latino; Numbers; Nursing Staff; Oncologic Nursing; Oncology Nurse; Ontology; Operative Surgical Procedures; Outpatients; Participant; Pathology, Other; Patient Care; Patients; Pennsylvania; Pharmaceutical Preparations; Pharmacogenomics; Pharmacy facility; Phase; Phase II Clinical Trials; Photochemotherapy; Physician Executives; Physicians; Play; Polysomnography; Population; Positioning Attribute; Postoperative Period; Preparation; Presbyterian Church; Prevention; Principal Investigator; Procedures; Program Development; Program Research Project Grants; Prostate; Protocols documentation; Published Comment; Purpose; Quality of life; R115777 (Zarnestra); Race; Radiation; Radiation Oncology; Randomized Controlled Clinical Trials; Recruitment Activity; Rectal Cancer; Reporting; Research; Research Institute; Research Personnel; Resource Sharing; Resources; Review Committee; Role; Schedule; Screening procedure; Series; Services; Site; Specific qualifier value; Standards of Weights and Measures; Stomach; Surgeon; Surgical Oncology; Suspension substance; Suspensions; Technology; Text; Therapeutic; Therapeutic Intervention; Time; Title; Training; Training and Education; Transplantation; Treatment Protocols; United States National Institutes of Health; Universities; University Hospitals; Visit; Work; anticancer research; base; bevacizumab; cancer research center director; chemotherapy; clinical epidemiology; colon carcinogenesis; cost; data management; drug development; experience; follow-up; gastrointestinal; human subject; improved; inhibitor/antagonist; innovation; interest; leukemia; lung cancer prevention; male; malignant breast neoplasm; malignant stomach neoplasm; member; metastatic colorectal; novel therapeutics; oncology; outreach program; oxaliplatin; patient oriented; pilot trial; pressure; probation; programs; sex; smoking cessation

DESCRIPTION (provided by applicant): The Abramson Cancer Center at the University of Pennsylvania was founded in 1973 as an interdisciplinary, interdepartmental research institute of the University of Pennsylvania. Since its inception, the Cancer Center has been continuously funded through the National Cancer Institute (NCI) core Support Grant, receiving five-year renewals in 1984, and 1989, and 1994, and 1999. The Cancer Center has been designated a Comprehensive Cancer Center by the NCI since the early 1970s and was re-designated as a comprehensive Cancer Center by the NCI in 1991. The University of Pennsylvania has had a long and successful track record in terms of scientific leadership, administrative involvement and excellent accrual to clinical trials with the Eastern Cooperative Oncology Group, with continuous funding for more than two decades. In late 2002, the ECOG Principal Investigators Committee reviewed the ECOG participation of the University of Pennsylvania, and found it to be among the strongest academic institutions in the Group, with outstanding scientific and administrative leadership. Data management was found to be good, and accrual acceptable, but continuous improvements in all areas of participation in ECOG activities remain the most important focus of this grant application. The areas in which anticipated improvements are targeted are: institutional support, faculty development, scientific contributions, data management organization and accrual enhancement.

描述（由申请人提供）：宾夕法尼亚大学的艾布拉姆森癌症中心成立于1973年，是宾夕法尼亚大学跨学科的跨学科研究所。 自成立以来，癌症中心一直通过国家癌症研究所（NCI）核心支持补助金持续资助，1984年，1989年，1989年以及1994年以及1999年获得了五年的续签。癌症中心自1970年代初以NCI指定为全面的癌症中心，并以NCI的全面癌症为中心，并被重新指定为NCI的全面癌症中心。 宾夕法尼亚大学在科学领导力，行政参与和与东部合作肿瘤学小组的临床试验方面取得了长期成功的往绩，并有持续的二十年来资助。 2002年底，ECOG首席研究人员委员会审查了宾夕法尼亚大学的ECOG参与，并发现它是该小组中最强的学术机构之一，具有出色的科学和行政领导。发现数据管理很好，可以接受，但是参与ECOG活动的所有领域的持续改进仍然是本赠款应用程序中最重要的重点。 预期改进的目标是：机构支持，教师发展，科学贡献，数据管理组织和应计增强。